Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE-2: PhosLo vs Renagel on Cardiac Calcification
NCT00211939Phase 4Completed
- Sponsor
- Nabi Biopharmaceuticals
- Start
- Jan 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Phoscat in hyperphosphatemia and calcinosis (2 arms), sponsored by Nabi Biopharmaceuticals. Primary endpoint: Coronary Artery Calcification at 12 months. Started Jan 2005; status: completed.
02
Drugs
Phoscat
03
Conditions
hyperphosphatemiacalcinosis
Beyond the preview
Go deeper on NCT00211939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211939.